ArticleBioinformatics (Oxford, England)2026
AXOLOTL: an accurate method for detecting aberrant gene expression in rare diseases using coexpression constraints.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
motivationThe assessment of aberrant transcription events in rare disease patients holds great promise for enhancing the prioritization of causative genes-a strategy already widely adopted in clinical settings to improve diagnostic accuracy. Nevertheless, the accurate identification of causal genes remains a substantial challenge.
resultsWe propose AXOLOTL, a novel ensemble method for identifying aberrant gene expression events in RNA expression matrices. AXOLOTL effectively accounts for gene correlation by incorporating coexpression constraints. We demonstrated the superior performance of AXOLOTL on representative RNA-seq datasets, including those from the GTEx healthy cohort, mitochondrial disease cohorts, and collagen VI-related dystrophy cohorts. Furthermore, we applied AXOLOTL to real-world cases of neurological disorders and demonstrated its ability to accurately identify aberrant gene expression and facilitate the prioritization of pathogenic variants. AVAILABILITY AND IMPLEMENTATION: AXOLOTL is freely available on GitHub (https://github.com/xuwenjian85/axolotl) and Zenodo (https://doi.org/10.5281/zenodo.17940844).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.